<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02706470</url>
  </required_header>
  <id_info>
    <org_study_id>2013SY034</org_study_id>
    <nct_id>NCT02706470</nct_id>
  </id_info>
  <brief_title>Use of Cyclosporin A for the Treatment of Recurrent Miscarriage</brief_title>
  <official_title>A Randomized, Controlled Trial of Cyclosporin A for Women With Unexplained Recurrent Miscarriage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Cyclosporin A (CsA) - an immunosuppressant
      drug - in early pregnancy will reduce the risk of miscarriage in women who had a history of
      unexplained recurrent miscarriages, as compared with that treated with Dydrogesterone-an
      active comparator. The hypothesis is based on the evidence found in vitro and in vivo
      experiments that CsA can induce maternal-fetal tolerance so that it may reduce the risk of
      miscarriage.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The difference in the live birth rates between patients with recurrent miscarriage assigned oral CsA and Dydrogesterone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference in the rate of miscarriage between patients with recurrent miscarriage treated with CsA and Dydrogesterone.</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The difference in the rates of miscarriage (pregnancy loss before 20 weeks gestation) between patients assigned oral CsA and Dydrogesterone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal death</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The difference in the rates of fetal death (fetal death after 20 weeks of gestational age) between patients assigned oral CsA and Dydrogesterone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in the rate of premature delivery between patients treated with CsA and Dydrogesterone.</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The difference in the rates of premature delivery (deliveries with gestational age less than 37 weeks) between patients assigned oral CsA and Dydrogesterone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital malformations</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The difference in the rates of congenital malformations between patients assigned oral CsA and Dydrogesterone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal outcomes: morbidity of infectious disease</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The difference of morbidity of infectious disease in pregnancy between two arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Miscarriage, Recurrent</condition>
  <arm_group>
    <arm_group_label>Cyclosporin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to Cyclosporin A group will receive oral Cyclosporin A in a dose of 50 mg three times a day for 20-30 days in early pregnancy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dydrogesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to dydrogesterone group will receive oral dydrogesterone in a dose of 10 mg three times a day for 30 days in early pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin A</intervention_name>
    <description>Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.</description>
    <arm_group_label>Cyclosporin A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone</intervention_name>
    <description>Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.</description>
    <arm_group_label>Dydrogesterone</arm_group_label>
    <other_name>Duphaston</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both the woman and her husband agree to participate and sign the informed consent
             form.

          -  Have a history of two or more unexplained recurrent miscarriages.

          -  Spontaneous conception.

          -  Gestational age less than 5 weeks.

          -  Have a normal menstrual cycle (&gt;=23 and &lt;=35 days) and biphasic pattern of basal body
             temperature before pregnancy.

          -  No significant chromosomal aberrations in the couple.

          -  Semen quality tests show not apparent abnormalities in husband

        Exclusion Criteria:

          -  Age below 18 or above 41 years at conception.

          -  Present pregnancy is a result of donor insemination or egg donation.

          -  Significant uterine anomalies detected by ultrasonography, hysterosalpingography, or
             hysteroscopy.

          -  Contraindications of CsA (e.g. severe infectious diseases, tumor or immunodeficiency)
             or Dydrogesterone.

          -  Smoking more than 20 daily.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dajin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Obstetrics &amp; Gynecology Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiangfeng Ye, MD</last_name>
    <phone>86-21-33189900</phone>
    <phone_ext>8386</phone_ext>
    <email>jiangfeng_ye@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meirong Du, MD</last_name>
    <phone>86-21-33189900</phone>
    <phone_ext>8386</phone_ext>
    <email>dmrlq1973@sina.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiangfeng Ye, MD</last_name>
      <phone>86-21-33189900</phone>
      <phone_ext>8386</phone_ext>
      <email>jiangfeng_ye@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Meirong Du, MD</last_name>
      <phone>86-21-33189900</phone>
      <phone_ext>8386</phone_ext>
      <email>dmrlq1973@sina.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Huang YH, Ma YL, Ma L, Mao JL, Zhang Y, Du MR, Li DJ. Cyclosporine A improves adhesion and invasion of mouse preimplantation embryos via upregulating integrin β3 and matrix metalloproteinase-9. Int J Clin Exp Pathol. 2014 Mar 15;7(4):1379-88. eCollection 2014.</citation>
    <PMID>24817934</PMID>
  </reference>
  <reference>
    <citation>Wang SC, Yu M, Li YH, Piao HL, Tang CL, Sun C, Zhu R, Li MQ, Jin LP, Li DJ, Du MR. Cyclosporin A promotes proliferating cell nuclear antigen expression and migration of human cytotrophoblast cells via the mitgen-activated protein kinase-3/1-mediated nuclear factor-κB signaling pathways. Int J Clin Exp Pathol. 2013 Sep 15;6(10):1999-2010. eCollection 2013.</citation>
    <PMID>24133577</PMID>
  </reference>
  <reference>
    <citation>Piao HL, Wang SC, Tao Y, Zhu R, Sun C, Fu Q, Du MR, Li DJ. Cyclosporine A enhances Th2 bias at the maternal-fetal interface in early human pregnancy with aid of the interaction between maternal and fetal cells. PLoS One. 2012;7(9):e45275. doi: 10.1371/journal.pone.0045275. Epub 2012 Sep 27.</citation>
    <PMID>23028901</PMID>
  </reference>
  <reference>
    <citation>Wang SC, Tang ChL, Piao HL, Zhu R, Sun Ch, Tao Y, Fu Q, Li DJ, Du MR. Cyclosporine A promotes in vitro migration of human first-trimester trophoblasts via MAPK/ERK1/2-mediated NF-κB and Ca2+/calcineurin/NFAT signaling. Placenta. 2013 Apr;34(4):374-80. doi: 10.1016/j.placenta.2013.01.009. Epub 2013 Feb 11.</citation>
    <PMID>23410723</PMID>
  </reference>
  <reference>
    <citation>Zhao HB, Tang CL, Hou YL, Xue LR, Li MQ, Du MR, Li DJ. CXCL12/CXCR4 axis triggers the activation of EGF receptor and ERK signaling pathway in CsA-induced proliferation of human trophoblast cells. PLoS One. 2012;7(7):e38375. doi: 10.1371/journal.pone.0038375. Epub 2012 Jul 27.</citation>
    <PMID>22848341</PMID>
  </reference>
  <reference>
    <citation>Tang CL, Zhao HB, Li MQ, Du MR, Meng YH, Li DJ. Focal adhesion kinase signaling is necessary for the Cyclosporin A-enhanced migration and invasion of human trophoblast cells. Placenta. 2012 Sep;33(9):704-11. doi: 10.1016/j.placenta.2012.06.007. Epub 2012 Jul 4.</citation>
    <PMID>22766276</PMID>
  </reference>
  <reference>
    <citation>Du MR, Zhou WH, Piao HL, Li MQ, Tang CL, Li DJ. Cyclosporin A promotes crosstalk between human cytotrophoblast and decidual stromal cell through up-regulating CXCL12/CXCR4 interaction. Hum Reprod. 2012 Jul;27(7):1955-65. doi: 10.1093/humrep/des111. Epub 2012 Apr 11.</citation>
    <PMID>22495096</PMID>
  </reference>
  <reference>
    <citation>Du MR, Zhou WH, Dong L, Zhu XY, He YY, Yang JY, Li DJ. Cyclosporin A promotes growth and invasiveness in vitro of human first-trimester trophoblast cells via MAPK3/MAPK1-mediated AP1 and Ca2+/calcineurin/NFAT signaling pathways. Biol Reprod. 2008 Jun;78(6):1102-10. doi: 10.1095/biolreprod.107.063503. Epub 2008 Mar 5.</citation>
    <PMID>18322274</PMID>
  </reference>
  <reference>
    <citation>Zhou WH, Dong L, Du MR, Zhu XY, Li DJ. Cyclosporin A improves murine pregnancy outcome in abortion-prone matings: involvement of CD80/86 and CD28/CTLA-4. Reproduction. 2008 Mar;135(3):385-95. doi: 10.1530/REP-07-0063.</citation>
    <PMID>18299432</PMID>
  </reference>
  <reference>
    <citation>Du MR, Zhou WH, Yan FT, Zhu XY, He YY, Yang JY, Li DJ. Cyclosporine A induces titin expression via MAPK/ERK signalling and improves proliferative and invasive potential of human trophoblast cells. Hum Reprod. 2007 Sep;22(9):2528-37. Epub 2007 Jul 18.</citation>
    <PMID>17636278</PMID>
  </reference>
  <reference>
    <citation>Zhou WH, Du MR, Dong L, Zhu XY, Yang JY, He YY, Li DJ. Cyclosporin A increases expression of matrix metalloproteinase 9 and 2 and invasiveness in vitro of the first-trimester human trophoblast cells via the mitogen-activated protein kinase pathway. Hum Reprod. 2007 Oct;22(10):2743-50. Epub 2007 Jun 12.</citation>
    <PMID>17566014</PMID>
  </reference>
  <reference>
    <citation>Du MR, Dong L, Zhou WH, Yan FT, Li DJ. Cyclosporin a improves pregnancy outcome by promoting functions of trophoblasts and inducing maternal tolerance to the allogeneic fetus in abortion-prone matings in the mouse. Biol Reprod. 2007 May;76(5):906-14. Epub 2007 Jan 17.</citation>
    <PMID>17229932</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <last_update_submitted>March 12, 2016</last_update_submitted>
  <last_update_submitted_qc>March 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jiangfeng Ye</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>recurrent miscarriage; immunology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

